G
Gynesonics
Gynesonics develops an ablation device for treating uterine fibroids.
About Gynesonics
Gynesonics is a medical technology company specializing in the development and commercialization of innovative solutions for women's health. The company operates in the healthcare sector, focusing on the treatment of symptomatic uterine fibroids. Its core product, the Sonata System, is the first and only intrauterine fibroid ablation system that combines the safety of ultrasound guidance with the benefits of targeted radiofrequency energy, all in a transcervical, incisionless procedure. This technology is designed to improve patient outcomes and reduce recovery times, offering a less invasive alternative to traditional surgical methods like myomectomy.
Gynesonics primarily serves healthcare providers, including hospitals and specialized gynecological clinics, that are looking for advanced, minimally invasive treatment options for their patients. The company operates in a market that is increasingly seeking cost-effective and efficient healthcare solutions, particularly in the field of women's health.
The business model of Gynesonics revolves around the sale and distribution of the Sonata System to medical facilities. Revenue is generated through the sale of the system itself, as well as through ongoing service and maintenance contracts. Additionally, the company benefits from positive payer coverage, which facilitates reimbursement from insurance providers, thereby expanding its market reach.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 1998
- Headquarters
- Redwood City, United States
- Employees
- 146
- Open positions
- None listed
- Dealroom signal
- 86.7/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, Gynaecological Health, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Oct 2024 | $350M | — | Hologic | ↗ |
| LATE VCOther financing | Nov 2023 | $43M | $375M | MVM Life Science Partners · Kaiser Permanente Ventures · Runway Growth Capital · Bain Capital | ↗ |
Growth signals
Latest recorded traffic for Gynesonics is 950 monthly website visits, down 40.6% over the last three months. Gynesonics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
Abingworth- AVAdvanced Technology Ventures
InterWest Partners
Series B and later11 investors entered at this stage
Correlation Ventures
HBM Partners
Bain Capital Life Sciences
Inc. Magazine
Endeavour Vision
Hercules Capital
Bain Capital
Runway Growth Capital
Kaiser Permanente Ventures
Amzak Health
MVM Life Science Partners
Other known investors1 additional known investor
Hologic
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Gynesonics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Gynesonics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.